NAMI has recently started endorsing the Partnership
for Prescription Assistance , a new program that seeks to boost
enrollment in existing Patient Assistance Programs by helping consumers
identify and apply for programs for which they may be eligible. This
may be a good place to start if you are unfamiliar with Assistance
Programs that might work for you - however, we don't yet know how
successful the Partnership is at enrolling people in good programs,
or how much they may charge for their service. If anyone has experiences
to share about the Partnership for Prescription Assistance (good or
bad), please email the administration at: szwebmaster@.
Visit their website ( http:// ) or call 1-888-477-2669 if you are interested.
Free information sites about PAPs - include databases searchable by state, medication, or company name
There are no well controlled studies with Haldol (haloperidol) in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of Haldol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to Haldol, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus.
† Please see full . prescribing information, including Black Box warning for: CONCERTA ® , DOXIL ® , DURAGESIC ® , HALDOL ® , HALDOL ® DECANOATE , INVEGA SUSTENNA ® , INVEGA TRINZA ® , INVOKAMET ® , INVOKAMET ® XR , INVOKANA ® , PROCRIT ® , REMICADE ® , RISPERDAL CONSTA ® , SIMPONI ® , SIMPONI ARIA ® , SPORANOX ® , SPORANOX ® ORAL SOLUTION , XARELTO ®